175 related articles for article (PubMed ID: 38305803)
1. Underlying mechanisms of novel cuproptosis-related dihydrolipoamide branched-chain transacylase E2 (DBT) signature in sunitinib-resistant clear-cell renal cell carcinoma.
Lai SW; Weng PW; Yadav VK; Pikatan NW; Yeh CT; Hsieh MS; Chou CL
Aging (Albany NY); 2024 Feb; 16(3):2679-2701. PubMed ID: 38305803
[TBL] [Abstract][Full Text] [Related]
2. Adrenomedullin/FOXO3 enhances sunitinib resistance in clear cell renal cell carcinoma by inhibiting FDX1 expression and cuproptosis.
Wang X; Jia JH; Zhang M; Meng QS; Yan BW; Ma ZY; Wang DB
FASEB J; 2023 Oct; 37(10):e23143. PubMed ID: 37698353
[TBL] [Abstract][Full Text] [Related]
3. A Novel Cuproptosis-Related Prognostic Gene Signature and Validation of Differential Expression in Clear Cell Renal Cell Carcinoma.
Bian Z; Fan R; Xie L
Genes (Basel); 2022 May; 13(5):. PubMed ID: 35627236
[TBL] [Abstract][Full Text] [Related]
4. Key sunitinib-related biomarkers for renal cell carcinoma.
Peng Y; Dong S; Song Y; Hou D; Wang L; Li B; Wang H
Cancer Med; 2021 Oct; 10(19):6917-6930. PubMed ID: 34402193
[TBL] [Abstract][Full Text] [Related]
5. Cuproptosis-Related 4-Gene Risk Model for Predicting Immunotherapy Drug Response and Prognosis of Kidney Renal Clear Cell Carcinoma.
Guo JS; Ding H; Wu PY; Xin ZY; Li JX; Jo HS; Ma ZH
Chin Med Sci J; 2023 Sep; 38(3):191-205. PubMed ID: 37503721
[TBL] [Abstract][Full Text] [Related]
6. Role of Sam68 in Sunitinib induced renal cell carcinoma apoptosis.
Wu Z; Peng Y; Xiong L; Wang J; Li Z; Ning K; Deng M; Wang N; Wei W; Li Z; Dong P; Yu C; Zhou F; Zhang Z
Cancer Med; 2022 Oct; 11(19):3674-3686. PubMed ID: 35476809
[TBL] [Abstract][Full Text] [Related]
7. Construction of cuproptosis signature based on bioinformatics and experimental validation in clear cell renal cell carcinoma.
Tian X; Zhu S; Liu W; Wu X; Wei G; Zhang J; Anwaier A; Chen C; Ye S; Che X; Xu W; Qu Y; Zhang H; Ye D
J Cancer Res Clin Oncol; 2023 Dec; 149(19):17451-17466. PubMed ID: 37889309
[TBL] [Abstract][Full Text] [Related]
8. Long noncoding RNA SNHG12 promotes tumour progression and sunitinib resistance by upregulating CDCA3 in renal cell carcinoma.
Liu Y; Cheng G; Huang Z; Bao L; Liu J; Wang C; Xiong Z; Zhou L; Xu T; Liu D; Yang H; Chen K; Zhang X
Cell Death Dis; 2020 Jul; 11(7):515. PubMed ID: 32641718
[TBL] [Abstract][Full Text] [Related]
9. Restoring the epigenetically silenced PCK2 suppresses renal cell carcinoma progression and increases sensitivity to sunitinib by promoting endoplasmic reticulum stress.
Xiong Z; Yuan C; Shi J; Xiong W; Huang Y; Xiao W; Yang H; Chen K; Zhang X
Theranostics; 2020; 10(25):11444-11461. PubMed ID: 33052225
[No Abstract] [Full Text] [Related]
10. Pan-cancer analysis of cuproptosis regulation patterns and identification of mTOR-target responder in clear cell renal cell carcinoma.
Long S; Wang Y; Chen Y; Fang T; Yao Y; Fu K
Biol Direct; 2022 Oct; 17(1):28. PubMed ID: 36209249
[TBL] [Abstract][Full Text] [Related]
11. Integrated single-cell and bulk characterization of cuproptosis key regulator PDHB and association with tumor microenvironment infiltration in clear cell renal cell carcinoma.
Wu J; Wang S; Liu Y; Zhang T; Wang X; Miao C
Front Immunol; 2023; 14():1132661. PubMed ID: 37350959
[TBL] [Abstract][Full Text] [Related]
12. Establishment of Sunitinib-Resistant Xenograft Model of Renal Cell Carcinoma and the Identification of Drug-Resistant Hub Genes and Pathways.
Xie Y; Shangguan W; Chen Z; Zheng Z; Chen Y; Zhong Q; Zhang Y; Yang J; Zhu D; Xie W
Drug Des Devel Ther; 2021; 15():5061-5074. PubMed ID: 34938069
[TBL] [Abstract][Full Text] [Related]
13. The cuproptosis-associated 13 gene signature as a robust predictor for outcome and response to immune- and targeted-therapies in clear cell renal cell carcinoma.
Yuan H; Qin X; Wang J; Yang Q; Fan Y; Xu D
Front Immunol; 2022; 13():971142. PubMed ID: 36131921
[TBL] [Abstract][Full Text] [Related]
14. Extracellular Vesicle-Mediated Transfer of LncRNA IGFL2-AS1 Confers Sunitinib Resistance in Renal Cell Carcinoma.
Pan Y; Lu X; Shu G; Cen J; Lu J; Zhou M; Huang K; Dong J; Li J; Lin H; Song H; Xu Q; Han H; Chen Z; Chen W; Luo J; Wei J; Zhang J
Cancer Res; 2023 Jan; 83(1):103-116. PubMed ID: 36264173
[TBL] [Abstract][Full Text] [Related]
15. Low DAPK1 expression correlates with poor prognosis and sunitinib resistance in clear cell renal cell carcinoma.
Song Z; Li Z; Han W; Zhu C; Lou N; Li X; Luo G; Peng S; Li G; Zhao Y; Guo Y
Aging (Albany NY); 2020 Nov; 13(2):1842-1858. PubMed ID: 33201837
[TBL] [Abstract][Full Text] [Related]
16. Construction and Validation of a Novel Cuproptosis-Related Seven-lncRNA Signature to Predict the Outcomes, Immunotherapeutic Responses, and Targeted Therapy in Patients with Clear Cell Renal Cell Carcinoma.
Zhang H; Ning Z; Wang B; Liu Y; Tao B; Zhang G; Liu H; Wang C
Dis Markers; 2023; 2023():7219794. PubMed ID: 36741910
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive analysis of a cuproptosis-related ceRNA network implicates a potential endocrine therapy resistance mechanism in ER-positive breast cancer.
Zhang D; Lu W; Zhuo Z; Wang Y; Zhang W; Zhang M
BMC Med Genomics; 2023 May; 16(1):96. PubMed ID: 37143115
[TBL] [Abstract][Full Text] [Related]
18. Multi-omics analysis uncovers clinical, immunological, and pharmacogenomic implications of cuproptosis in clear cell renal cell carcinoma.
Zhu M; Li Y; Wang Y; Lin P; Mi J; Zhong W
Eur J Med Res; 2023 Jul; 28(1):248. PubMed ID: 37481601
[TBL] [Abstract][Full Text] [Related]
19. A novel FBW7/NFAT1 axis regulates cancer immunity in sunitinib-resistant renal cancer by inducing PD-L1 expression.
Liu W; Ren D; Xiong W; Jin X; Zhu L
J Exp Clin Cancer Res; 2022 Jan; 41(1):38. PubMed ID: 35081978
[TBL] [Abstract][Full Text] [Related]
20. Y-box binding protein-1 is crucial in acquired drug resistance development in metastatic clear-cell renal cell carcinoma.
D'Costa NM; Lowerison MR; Raven PA; Tan Z; Roberts ME; Shrestha R; Urban MW; Monjaras-Avila CU; Oo HZ; Hurtado-Coll A; Chavez-Munoz C; So AI
J Exp Clin Cancer Res; 2020 Feb; 39(1):33. PubMed ID: 32041631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
